Decipher Biosciences

Decipher Biosciences, operating as the core urology franchise within Veracyte, Inc., is dedicated to transforming cancer care through genomic diagnostics. The company has achieved significant commercial success and clinical validation with its Decipher Prostate and Decipher Bladder tests, which are now integral tools for risk stratification in prostate and bladder cancer management. Its strategy centers on expanding clinical utility, driving adoption through key guideline inclusion and payer coverage, and leveraging its genomic database to fuel research and development. Decipher aims to solidify its leadership in urologic oncology by continuously generating evidence and exploring new applications for its platform.

A genomic profiling platform that analyzes RNA expression from FFPE tumor tissue to provide prognostic and predictive risk scores and molecular subtypes for urologic cancers.

Decipher competes with other genomic tests like Myriad's Prolaris and Exact Sciences' Oncotype DX in prostate cancer, but holds a strong position due to its robust clinical validation and top-tier NCCN guideline rating. In bladder cancer, it faces less direct commercial competition but must demonstrate superior utility against research-use-only molecular classifications.